echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Legend Bio's cilta-cel has been approved by the FDA for the launch of domestic CAR-T target competition

    Legend Bio's cilta-cel has been approved by the FDA for the launch of domestic CAR-T target competition

    • Last Update: 2022-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Textrainbow

    On February 28th, Eastern Time, the US FDA officially approved Legend Bio’s BCMA-targeting chimeric antigen receptor T cell (CAR-T) product, Ciltacabtagene autoleucel (cilta-cel, Cidaki Orenza, trade name Carvykti) )


    cilta-cel is a BCMA-targeted CAR-T therapy independently developed by Legend Bio for the treatment of adult relapsed and/or refractory multiple myeloma (R/RMM), containing a 4-1BB co-stimulatory structure domain and two BCMA-targeting single-domain antibodies


    This time, Legend Bio cilta-cel was officially approved for listing in the United States, becoming the first successful example of China's first self-developed CAR-T product to go overseas


    cilta-cel: Legend Bio's CAR-T therapy "leader"

    cilta-cel: Legend Bio's CAR-T therapy "leader"

    cilta-cel is Legend Bio’s product that became famous in one fell swoop, and there was no lack of “charm” in terms of regulatory dynamics before:

    In 2018, the therapy obtained the first CAR-T clinical trial application (IND) approval from the China National Medical Products Administration and IND approval from the US FDA; Breakthrough Therapy Designation granted by the U.


    It is reported that the submission of cilta-cel's marketing application (BLA) is mainly based on the results of the pivotal Phase Ib/II CARTITUDE-1 study, which evaluated the efficacy of ciltacel in patients with relapsed and/or refractory multiple myeloma and security


    At a median follow-up of 12.


    In addition to the previously outstanding clinical data, at the 40th JPMorgan Chase Healthcare Annual Conference not long ago, Dr.


    In addition to this cilta-cel, which is running at the end of regulatory victory, in the field of hematology, Legend Bio has developed single-target/dual-target/triple-target CAR-T products targeting multiple potential targets, including BCMA, CD4, CD20, CD33/CLL-1, CD19/CD20/CD22,


    It is worth noting that earlier this month, Legend Bio received an email from the FDA stating that the Phase I clinical trial of its LB1901 was suspended


    In the field of solid tumors, Legend Bio has developed a number of products to deal with gastric cancer, liver cancer, small cell lung cancer, non-small cell lung cancer and ovarian cancer.


    In addition, Legend Bio also owns a Chimeric Antigen Receptor Natural Killer Cell (CAR-NK) platform


    The CAR-T market has broad prospects, and the first targeted BCMA product is facing its rivals

    The CAR-T market has broad prospects, and the first targeted BCMA product is facing its rivals

    CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy) cell therapy has been proven to be a powerful weapon against blood cancers


    Up to now, the US FDA has approved 6 CAR-T cell therapies, of which four target CD19 and two target BCMA


    On the market side, according to Frost & Sullivan, the global CAR-T cell therapy market has grown from US$100 million in 2017 to US$700 million in 2019 and US$1.


    According to the 2021 results announcements recently released by major pharmaceutical companies:

    Novartis' Kymriah, the first to go public, has sales of $587 million in 2021, up 24% year over year


    And cilta-cel, as the world's second approved BCMA-targeting CAR-T therapy, is the most direct competitor after it - Abecma from Bristol-Myers Squibb from the same track.


    However, based on previous clinical data, Abecma-treated patients with prior Category 3 therapy had a median OS of 24.
    8 months, ORR was 73%, and 33% of patients achieved CR
    .
    As mentioned above, the clinical data of Legend Bio cilta-cel showed that its ORR reached 98%, 80% of patients achieved sCR, and the safety also had certain differentiated advantages
    .

    It can be seen that the sales of cilta-cel in the future may be slightly better
    .

    It is understood that the legendary creature has been favored by the giant MNC long before cilta-cel took shape
    .
    In December 2017, Legend Bio reached a global cooperation and licensing agreement with Janssen, a subsidiary of Johnson & Johnson
    .
    According to the cooperation agreement, in the Greater China region, Legend Bio and Janssen jointly bear the costs and share the benefits in a ratio of 7:3; in other regions of the world, the two companies will share 50-50
    .

    At present, Legendary Bio has received an upfront payment of $350 million and a milestone payment of $250 million
    .

    Domestic companies are unwilling to lag behind, and CAR-T target competition is poised to take off

    Domestic companies are unwilling to lag behind, and CAR-T target competition is poised to take off

    Domestically, the State Food and Drug Administration has approved the listing of two CAR-T products, both targeting CD19
    .
    These two products are Fosun Kite's akirenxe injection and WuXi Junuo's Ruijiorenxe injection.
    It is reported that both products are co-introduced products.
    Kate was introduced to Kite Company, and Ruiki Orenza Injection was introduced to Juno Company by WuXi Ju Nuo
    .

    It is worth mentioning that on February 27, WuXi Junuo announced that the second indication of its CAR-T product, Ruiki Aurenzai Injection, has been accepted by the State Food and Drug Administration for the treatment of recurrence.
    or refractory (r/r) follicular lymphoma (FL)
    .

    In addition, domestic companies such as Heyuan Bio, Keji Pharmaceutical, and Yimiao Shenzhou have actively joined in, and all of their products have entered the clinical stage
    .
    Its research and development targets mainly focus on CD19, followed by BCMA, and there are also dual-target products
    .

    Reference source: Yaodu "Global CAR-T Therapy R&D Guide"

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.